Neurochemical aspects of the sexual response cycle

CNS Spectrums

Volumn 8, Issue 3, 2003, Pages 211-216

  Halaris, Angelos ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; NEUROTRANSMITTER; NITRIC OXIDE; OXYTOCIN; PROGESTERONE; PROLACTIN; SILDENAFIL; DOPAMINE; SEROTONIN; SEX HORMONE;

ADRENERGIC SYSTEM; BRAIN; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; ENDOCRINE SYSTEM; NERVOUS SYSTEM; NEUROCHEMISTRY; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; FEMALE; HUMAN; IMPOTENCE; LIBIDO; MALE; METABOLISM; PHYSIOLOGY;

BRAIN; DOPAMINE; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMPOTENCE; LIBIDO; MALE; NITRIC OXIDE; OXYTOCIN; PROLACTIN; SEROTONIN; SEXUAL BEHAVIOR;

EID: 0037364131     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900024445     Document Type: Review

References (76)

1. Halaris A. Sex and the brain. In: Halaris A, ed. Bailliere's Clinical Psychiatry: Sexual Dysfunction. London, England: Bailliere Tindall; 1997:25-42.
2. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57:1012-1030.
3. Segraves RT. Bethanechol reversal of imipramine-induced ejaculatory dysfunction. Am J Psychiatry. 1987;144:1243.
4. Blanco R, Saenz de Tejada I, Goldstein I, et al. Cholinergic neurotransmission in human corpus cavernosum, II: acetylcholine synthesis. Am J Physiol. 1988;254:H468-H472.
5. Godec CJ, Bates H. Cholinergic receptors in corpus cavernosum. Urology. 1984;24:31-33.
6. Kruger T, Exton MS, Pawlak C, et al. Neuroendocrine and cardiovascular response to sexual arousal and orgasm in men. Psychoneuroendocrinology. 1998:23:401-411.
7. Meston CM, Heiman JR. Ephedrine-activated physiological sexual arousal in women. Arch Gen Psychiatry. 1998;55:652-656.
8. Morales A, Condra M, Owen JA, et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol. 1987;137:1168-1172.
9. Susset JG, Tessier CD, Wincze J, et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. 1989;141:1360-1363.
10. Sonda LP, Mazo R, Chancellor MB. The role of yohimbine for the treatment of erectile impotence. J Sex Marital Ther. 1990;16:15-22.
11. Piletz JE, Segraves KB, Feng Y, et al. Plasma MHPG response to yohimbine: treatment in women with hypoactive sexual desire. J Sex Marital Ther. 1998;24:43-54.
12. Everitt BJ. Sexual motivation: a neural and behavioral analysis of the mechanisms underlying appetitive and copulatory responses of male rats. Neuroscience Biobehavior Rev. 1990;14:217-232.
13. Everitt BJ, Bancroft J. Of rats and men: the comparative approach to male sexuality. Annu Rev Sexual Res. 1991;2:77-118.
14. Bowers MB, Van Woert M, Davis L. Sexual behavior during L-dopa treatment for Parkinsonism. Am J Psychiatry. 1970;127:1691-1693.
15. Angrist B, Gershon B. Clinical effects of amphetamine and L-dopa on seuality and aggression. Comp Psychiatry. 1976;17:715-722.
16. Frajese G, Rocco A, Falashi P, et al. Reproductive parameters in prolactinaemic men. Arch Androl. 1983;10:179-183.
17. Lal S, Ackman D, Tharundayil JX, et al. Effects of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Progress Neurol Psychopharmacol Biol Psychiatry. 1984;8:695-699.
18. Lal S, Laryea E, Tharundayil JX, et al. Apomorphine-induced penile tumescence in impotent patients-preliminary findings. Progress Neurol Psychopharmacol Biol Psychiatry. 1987;11:235-242.
19. Lal S, Tesfaye Y, Tharundayil JX, et al. Apomorphine: clinical studies on erectile functioning and yawning. Progress Neurol Psychopharmacol Biol Psychiatry. 1989;13:329-339.
20. Danjou P, Alexander L, Warot D, et al. Assessment of erotogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol. 1988;26:733-739.
21. Segraves RT, Bari M, Segraves K, Spirnak P. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol. 1991;145:1174-1175.
22. Miller NS, Gold MS. The human sexual response and alcohol and drugs. J Subst Abuse Treat. 1988;5:171-177.
23. Cohen S. Cocaine. JAMA. 1975;231:74-75.
24. Smith DE, Wesson DR, Apter-Marsh M. Cocaine and alcohol-induced sexual dysfunction in patients with addictive disease. J Psychoactive Drugs. 1984;16:359-361.
25. Meston CM, Gorzalka BB. Psychoactive drugs and human sexual behavior: the role of serotonergic activity. J Psychoactive Drugs. 1992;24:1-40.
26. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry. 1996;57:(suppl 20):53-62.
27. Preskom SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12-21.
28. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23:176-193.
29. Tagliamonte A, Tagliamonte P, Gessa GL, Brodie BB. Compulsive sexual activity induced by p-chlorophenylalanine in normal and pinealectomized rats. Science. 1969;166:1433-1435.
30. Stevenson RWD, Solyom D. The aphrodisiac effect of fenfluramine: two case reports of a possible side effect to the use. J Clin Psychiatry. 1990;10:69-71.
31. Gartrell N. Increased libido in women receiving trazodone. Am J Psychiatry. 1986;143:781-782.
32. Sullivan G. Increased libido in three men treated with trazodone. J Clin Psychiatry. 1988;49:202-203.
33. Woodrum ST, Brown CS. Management of SSRI-induced sexual dysfunction. Ann Pharmacother. 1998;32:1209-1215.
34. Chiueh C, Hong J-S, Leong S, eds. Nitric Oxide. New York, NY: Annals of the New York Academy of Sciences; 2002.
35. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Eng J Med. 1992;326:90-94.
36. Burnett AL, Calvin DC, Silver RI, et al. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol. 1997;158:75-78.
37. Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral Sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999;53:1011-1018.
38. Dinsmore WW, Hodges M, Hargreaves C, et al. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology. 1999;53;800-805.
39. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.
40. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology. 1999;53:481-486.
41. Ashton AK. Sildenafil treatment of paroxetine-induced anorgasmia in women. Am J Psychiatry. 1999;156:800.
42. Ashton AK, Bennett RG. Sildenafil treatment of serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 1999;60:194-195.
43. Nurnberg HG, Hensley PL, Lauriello J, et al. Sildenafil for women patients with antidepressant-induced sexual dysfunction. Psychiatr Serv. 1999;50:1076-1078.
44. Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metabolism. 1983;57:557-562.
45. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertile Steril. 1985;43:90-94.
46. Halpern CR, Udry JR, Suchindran C. Monthly measures of salivary testosterone predict sexual activity in adolescent males. Arch Sex Behav. 1998;27;445-465.
47. Schiavi RC, White D. Androgen and male sexual function: A review of human studies. J Sex Marital Ther. 1976;2:214-228.
48. O'Carroll R, Shapiro C, Bancroft J. Androgens, behavior and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol. 1985;23:527-538.
49. Alexander GM, Swerdloff RS, Wang CW, Davidson T. Androgen-behavior correlations in hypogonadal men and eugonadal men I: mood and response to auditory sexual stimuli. Horm Behav. 1997;31:110-119.
50. Ehrenreich H, Halaris, A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Resear. 1999;33:379-387.
51. Sands R, Stud J. Exogenous androgens in postmenopausal women. Am J Med. 1995;98(suppl 1A):76s-79s.
52. Rako S. The Hormone of Desire: The Truth about Sexuality, Menopause and Testosterone. New York, NY: Harmony Books; 1996.
53. Warnock JK, Bundren JC, Morris DW. Female hypoactive sexual desire disorder due to androgen deficiency: clinical and psychometric issues. Psychopharmacol Bull. 1997;33:761-766.
54. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study in sex steroid administration in the surgical menopause. Psychosom Med. 1985;47:339-351.
55. Gelfand MM. Treating menopausal symptoms with estrogen and androgen preparations. Contemp Obstet/Gynecol. 1994;31-36.
56. Redmond GP. Hormones and sexual function. Int J Fertil. 1999;44:193-197.
57. Halpern CT, Udry J, Suchindran C. Testosterone predicts initiation of coitus in adolescent females. Psychosom Med. 1997;59:161-171.
58. Persky H, Charney N, Lief HI et al. The relationship of plasma estradiol level to sexual behavior in young women. Psychosom Med. 1978;40:523-535.
59. Abplanalp JM, Rose RM, Donnelly AF, Livingston-Vaughn L. Psychoendocrinology of the menstrual cycle: II. The relationship between enjoyment of activities, moods and reproductive hormones. Psychosom Med. 1979;41:605-615.
60. Sherwin B. Changes in sexual behavior as a function of plasma sex steroid levels in postmenopausal women. Maturitas. 1985;7:225-233.
61. Berman JR, Goldstein I. Female sexual dysfunction. Urol Clin North America. 2001;28:405-416.
62. Berman JR, Berman I, Goldstein I. Female sexual dysfunction: Incidence, pathophysiology, evaluation, and treatment options. Urology. 1999;54:385-391.
63. Warner P, Bancroft J. Mood, sexuality, oral contraceptives and the menstrual cycle. J Psychosom Res. 1988;32:417-427.
64. Bouloux PM, Grossman A. Hyperprolactinemia and sexual function in the male. Brit J Hosp Med. 1987;37:503.
65. Schwartz MF, Bauman JE, Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psych. 1982;17:861-876.
66. Foster RS, Mulcahy JJ, Callaghan JT, et al. Role of serum prolactin determination in evaluation of impotent patient. Urol. 1990;36:499-501.
67. Hulter B, Lundberg PO. Sexual function in women with hypothalamo-pituitary disorders. Arch Sex Behav. 1994;23:171-183.
68. Kayner CE, Zager JA. Breast-feeding and sexual response. J Fam Pract. 1983;17:69-73.
69. Koppelman MCS, Parry BL, Hamilton JA, et al. Effect of bromocriptine on mood, affect and libido in hyperprolactinemia. Am J Psychiatry. 1987;144:1037-1041.
70. Shukovski I, Findlay JK, Smith AI. Identification of a non-covalent oxytocin/neurophysin-1 complex in the bovine ovary. J Endocrinol. 1991;128:305-314.
71. Murphy MR, Seckl JR, Burton S, et al. Changes in oxytocin and vasopressin secretion during sexual activity in men. J Clin Endocrinol. 1987;65:738-741.
72. Carmichael MS, Humbert R, Dixen J, et al. Plasma oxytocin increases in the human sexual response. J Endocrinol Metab. 1987;64:27-31.
73. Carmichael MS, Warburton VL, Dixen J, et al. Relationships among cardiovascular, muscular, and oxytocin responses during human sexual activity. Arch Sex Behav. 1994;23:59-77.
74. Anderson-Hunt M, Dennerstein L. Increased female sexual response after oxytocin. Br Med J. 1994;309:929.
75. Anderson-Hunt M, Dennerstein L. Oxytocin and female sexuality. Gynecol Obstet Invest. 1995;40:217-221.
76. Insel TR. A neurobiological basis of social attachment. Am J Psychiatry. 1997;154:727-735.